Literature DB >> 16965729

Current understanding of optimal blood pressure goals in dialysis patients.

Paul Light1.   

Abstract

The hemodialysis population is associated with a very low survival rate, with myocardial infarctions and strokes accounting for most of the increased mortality. Recent observational studies demonstrate a paradoxical relationship between increasing blood pressure and increasing mortality. Hypertension treated with antihypertensive medications unequivocally reduces cerebrovascular risk, but demonstration of a survival benefit for cardiovascular mortality has proven more difficult to demonstrate. Increased pulse pressure is caused by inadequate dialysis treatment that increases arterial wall stiffness and afterload, and decreases coronary perfusion. The disproportionate representation of diastolic dysfunction and coronary artery atherosclerosis may explain why increased pulse pressure is associated with higher cardiovascular risk for the dialysis population. Optimum blood pressure control has not been established, due to a lack of prospective studies targeting blood pressure reduction. Opinion-based recommendations are offered, but goals should be individualized based on a complete assessment of prevailing comorbidities and should target normalization of the pulse pressure.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16965729     DOI: 10.1007/s11906-006-0088-6

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  46 in total

1.  Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin.

Authors:  A Levin; C R Thompson; J Ethier; E J Carlisle; S Tobe; D Mendelssohn; E Burgess; K Jindal; B Barrett; J Singer; O Djurdjev
Journal:  Am J Kidney Dis       Date:  1999-07       Impact factor: 8.860

2.  The clinical course of left ventricular hypertrophy in dialysis patients.

Authors:  P S Parfrey; J D Harnett; S M Griffiths; R Taylor; J Hand; A King; P E Barre
Journal:  Nephron       Date:  1990       Impact factor: 2.847

3.  Hypertension in dialysis patients: a cross-sectional analysis.

Authors:  M Tozawa; K Iseki; K Fukiyama
Journal:  Nihon Jinzo Gakkai Shi       Date:  1996-03

4.  Hypertension in the haemodialysis population: any relationship to 2-years survival?

Authors:  M M Salem
Journal:  Nephrol Dial Transplant       Date:  1999-01       Impact factor: 5.992

5.  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.

Authors: 
Journal:  JAMA       Date:  1991-06-26       Impact factor: 56.272

6.  Survival as an index of adequacy of dialysis.

Authors:  B Charra; E Calemard; M Ruffet; C Chazot; J C Terrat; T Vanel; G Laurent
Journal:  Kidney Int       Date:  1992-05       Impact factor: 10.612

7.  Comparison of causes of death using HEMO Study and HCFA end-stage renal disease death notification classification systems. The National Institutes of Health-funded Hemodialysis. Health Care Financing Administration.

Authors:  Michael V Rocco; Guofen Yan; Jennifer Gassman; Julia Breyer Lewis; Daniel Ornt; Barbara Weiss; Andrew S Levey
Journal:  Am J Kidney Dis       Date:  2002-01       Impact factor: 8.860

8.  Central pulse pressure and mortality in end-stage renal disease.

Authors:  Michel E Safar; Jacques Blacher; Bruno Pannier; Alain P Guerin; Sylvain J Marchais; Pierre-Marie Guyonvarc'h; Gérard M London
Journal:  Hypertension       Date:  2002-03-01       Impact factor: 10.190

9.  Secular trends in long-term sustained hypertension, long-term treatment, and cardiovascular mortality. The Framingham Heart Study 1950 to 1990.

Authors:  P A Sytkowski; R B D'Agostino; A J Belanger; W B Kannel
Journal:  Circulation       Date:  1996-02-15       Impact factor: 29.690

10.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.